You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

 

624 Results
Document
Jul 2018
Document
Jul 2018
Document
Jul 2018
Document
Dec 1969
Regimen
Cancer Type:
Hematologic, 
Lymphoma - T-cell
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Pralatrexate - Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
PRALAtrexate,
leucovorin
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Sep 2023
Document
Dec 1969
Document
Sep 2018
Document
Sep 2018
La perturbation du service de Postes Canada pourrait avoir une influence sur la livraison des lettres de dépistage du cancer et des trousses de tests...
Guidelines and Advice
Status: Current
ID: pet 2018-1
Version: n/a
Oct 2018
Regimen
Cancer Type:
Breast
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
ODB - General Benefit
    exemestane
Exceptional Access Program
    ribociclib - For the treatment of patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER 2)-negative, unresectable locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant according to clinical criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
exemestane,
ribociclib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Sep 2025
Regimen
Cancer Type:
Breast
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
ODB - General Benefit
    exemestane
Exceptional Access Program
    palbociclib - For the treatment of patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER 2)-negative, unresectable locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant, according to clinical criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
exemestane,
palbociclib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Sep 2025

Pages